GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • NEW YORK, June 17- Merck& Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks traded lower as uncertainty over Greece weighed on sentiment and investors kept an eye on bond yields ahead of next week's FOMC meeting.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?

  • June 8- Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Januvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in...

  • June 4- A bipartisan group of U.S. lawmakers introduced legislation on Thursday to boost protections for pregnant workers in response to a recent U.S. Supreme Court ruling that revived discrimination claims by a former United Parcel Service Inc driver. The group of lawmakers backing the bill includes Senator Kelly Ayotte, a Republican from New Hampshire, but...

  • 10 cheap stocks for an overvalued market Wednesday, 3 Jun 2015 | 8:47 AM ET
    A Merck sign in front of the company's building in Summit, New Jersey.

    CNBC Pro found some of the stocks that are trading at a discount and have solid growth expectations for the future.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower on the last trading day of the month, as investors digested data and remained cautious on continued concerns about Greece.

  • These biotechs may surge on drug news: Expert Friday, 29 May 2015 | 3:31 PM ET
    Lab science research

    Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.

  • Here's why Puma, Clovis shares are poised to move Friday, 29 May 2015 | 2:49 PM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • One trader’s very contrarian pharma trade Wednesday, 27 May 2015 | 10:22 AM ET

    Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.

  • CHICAGO/ NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps- importing eggs from overseas or looking to egg alternatives. A spokeswoman for Archer Daniels Midland Co said that as egg supplies tighten and prices rise, the food processing...

  • May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.

  • CHICAGO and NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps: importing eggs from overseas or looking to egg alternatives. "Canada is short on eggs and has been buying heavily from the U.S. for the last several years," said Rick Brown, a...

  • Europe ends sharply higher on ECB QE pledge Tuesday, 19 May 2015 | 11:30 AM ET

    European equities finished sharply higher, with investors reacting to corporate earnings and focusing on comments by a member of the ECB.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...